TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT04729114: Phase 1, Open-Label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer

Sponsor: Astellas Pharma Global Development, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 174 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$6,817,272

Rescue Site Savings

+$4,492,488

Unlock Full NCT04729114 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04729114 Rescue Dossier →